PREMAL LULLA to T-Lymphocytes
This is a "connection" page, showing publications PREMAL LULLA has written about T-Lymphocytes.
Connection Strength
2.932
-
Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27.
Score: 0.448
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.400
-
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
Score: 0.366
-
Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540.
Score: 0.298
-
Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9.
Score: 0.296
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.128
-
Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024 12 31; 20(1):2378543.
Score: 0.125
-
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
Score: 0.111
-
CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2022 03 03; 139(9):1266-1267.
Score: 0.106
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.098
-
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
Score: 0.090
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.077
-
Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
Score: 0.077
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.077
-
Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396.
Score: 0.074
-
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
Score: 0.032
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.031
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.031
-
Banking on virus-specific T cells to fulfill the need for?off-the-shelf cell therapies. Blood. 2023 02 23; 141(8):877-885.
Score: 0.028
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.021
-
Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
Score: 0.019